Generate Biomedicines Inc (GENB)

$17.14 +0.02 (0.12%)
Market Cap 2.20B
Revenue (ttm) 31.89M
Net Income (ttm) -203.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -637.03%
Debt to Equity Ratio 0.00
Volume 1,404,400
Avg Vol 1,012,740
Day's Range N/A - N/A
Shares Out 128.35M
Stochastic %K 75%
Beta N/A
Analysts Strong Sell
Price Target $27.00

Company Profile

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5...

Industry: Biotechnology
Sector: Healthcare
Phone: (888) 469-0055
Address:
101 South Street, Suite 900, Somerville, United States
Too026
Too026 Sep. 16 at 8:30 AM
$GENB today up to 17
1 · Reply
MavrickPete
MavrickPete Sep. 7 at 9:57 PM
$GENB First cohort fully enrolled; program has FDA Fast Track designation...
0 · Reply
CaesarZane
CaesarZane Sep. 6 at 7:24 PM
$NBIS $GENB $INTC 🚀🚀🚀 https://youtu.be/cEbwSb9BQ0U
1 · Reply
BADBRAIN
BADBRAIN Sep. 4 at 9:38 PM
$GENB At the European Respiratory Society (ERS) Congress 2026, Generate will present three posters on GB-0895 in COPD and severe asthma. The COPD poster will present safety, pharmacokinetic, and pharmacodynamic data from the ongoing Phase 1b study in adults with COPD on Sept. 8. Two additional posters will present complete Phase 1 data in asthma and the design of the ongoing SOLAIRIA-1 and SOLAIRIA-2 replicate Phase 3 studies in severe asthma.
0 · Reply
martinlees
martinlees Sep. 4 at 12:05 PM
$GENB looking at 60
0 · Reply
rventures
rventures Aug. 30 at 11:01 PM
$GENB riding this back to $25
0 · Reply
JSullivan2018
JSullivan2018 Aug. 27 at 7:51 PM
$GENB wtf
0 · Reply
DataClown
DataClown Aug. 27 at 2:32 AM
$GENB Bearish near-term. The −20.8% wasn't a verdict on the science — it was arithmetic: unlocking 68M shares onto a 60M-share float is dilution with extra steps.
0 · Reply
rventures
rventures Aug. 26 at 7:05 PM
$GENB time to get back in and sell at $20-22 again
1 · Reply
mobirdmeat
mobirdmeat Aug. 26 at 6:37 PM
$GENB Do you think this will move with $NVDA earnings ? $GRRR $ANF $BHVN
0 · Reply
Latest News on GENB
Generate Biomedicines Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 16, 2026, 10:30 AM EDT - 2 days ago

Generate Biomedicines Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Generate Biomedicines Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Sep 14, 2026, 7:00 AM EDT - 4 days ago

Generate Biomedicines Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Generate Biomedicines Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2026, 3:55 PM EDT - 9 days ago

Generate Biomedicines Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Generate Biomedicines Inc. to Participate in September Investor Conferences

Sep 8, 2026, 7:09 AM EDT - 10 days ago

Generate Biomedicines Inc. to Participate in September Investor Conferences

Generate Biomedicines price target raised to $30 from $25 at H.C. Wainwright

2026-08-28T10:10:29.000Z - 21 days ago

Generate Biomedicines price target raised to $30 from $25 at H.C. Wainwright

Generate Biomedicines falls -16.7%

2026-08-26T16:05:29.000Z - 23 days ago

Generate Biomedicines falls -16.7%

Generate Biomedicines falls -11.0%

2026-08-26T14:05:22.000Z - 23 days ago

Generate Biomedicines falls -11.0%

Generate Biomedicines rises 17.7%

2026-08-25T16:06:10.000Z - 24 days ago

Generate Biomedicines rises 17.7%

Generate Biomedicines reports Q2 EPS (52c), consensus (49c)

2026-08-06T12:06:48.000Z - 6 weeks ago

Generate Biomedicines reports Q2 EPS (52c), consensus (49c)

Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 6, 2026, 7:00 AM EDT - 6 weeks ago

Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 6 weeks ago

Generate Biomedicines Quarterly report: Q2 2026

Generate Biomedicines Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 6 weeks ago

Generate Biomedicines Earnings release: Q2 2026

Generate Biomedicines falls -9.5%

2026-07-10T16:05:32.000Z - 2 months ago

Generate Biomedicines falls -9.5%

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Jun 22, 2026, 8:00 AM EDT - 2 months ago

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Generate Biomedicines Slides: Corporate presentation

Jun 9, 2026, 7:00 AM EDT - 3 months ago

Generate Biomedicines Slides: Corporate presentation

Generate Biomedicines Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 3:20 PM EDT - 3 months ago

Generate Biomedicines Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

May 28, 2026, 4:20 PM EDT - 3 months ago

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Generate Biomedicines price target raised to $22 from $20 at Morgan Stanley

2026-05-14T16:37:25.000Z - 4 months ago

Generate Biomedicines price target raised to $22 from $20 at Morgan Stanley

Generate Biomedicines price target raised to $25 from $16 at H.C. Wainwright

2026-05-08T10:32:33.000Z - 4 months ago

Generate Biomedicines price target raised to $25 from $16 at H.C. Wainwright

Generate Biomedicines Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 months ago

Generate Biomedicines Quarterly report: Q1 2026

Generate Biomedicines Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 months ago

Generate Biomedicines Earnings release: Q1 2026

Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M

2026-05-07T11:16:37.000Z - 4 months ago

Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026, 6:16 AM EDT - 4 months ago

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines initiated with a Buy at H.C. Wainwright

2026-04-13T10:18:45.000Z - 5 months ago

Generate Biomedicines initiated with a Buy at H.C. Wainwright

Generate Biomedicines Slides: Corporate presentation

Apr 8, 2026, 7:00 AM EDT - 5 months ago

Generate Biomedicines Slides: Corporate presentation

Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald

2026-03-24T11:56:18.000Z - 5 months ago

Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald

Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald

2026-03-24T10:25:46.000Z - 5 months ago

Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald

Generate Biomedicines initiated with a Buy at Guggenheim

2026-03-24T09:15:42.000Z - 5 months ago

Generate Biomedicines initiated with a Buy at Guggenheim

Generate Biomedicines initiated with an Overweight at Morgan Stanley

2026-03-24T09:10:12.000Z - 5 months ago

Generate Biomedicines initiated with an Overweight at Morgan Stanley

Generate Biomedicines initiated with an Overweight at Piper Sandler

2026-03-24T09:00:31.000Z - 5 months ago

Generate Biomedicines initiated with an Overweight at Piper Sandler

Generate Biomedicines initiated with a Buy at Goldman Sachs

2026-03-24T08:35:11.000Z - 5 months ago

Generate Biomedicines initiated with a Buy at Goldman Sachs

Generate Biomedicines Slides: Corporate presentation

Mar 6, 2026, 6:00 AM EST - 6 months ago

Generate Biomedicines Slides: Corporate presentation

Opening Day: Generate Biomedicines makes public debut

2026-03-02T16:30:40.000Z - 6 months ago

Opening Day: Generate Biomedicines makes public debut

AGMB BOBS EIKN FPS FVAV MANE OFRM

Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut

Feb 27, 2026, 12:57 PM EST - 6 months ago

Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut

Generate Biomedicines opens at $15.00, IPO priced at $16.00

2026-02-27T17:55:43.000Z - 6 months ago

Generate Biomedicines opens at $15.00, IPO priced at $16.00

Drug developer Generate Biomedicines raises $400 million in US IPO

Feb 26, 2026, 8:11 PM EST - 6 months ago

Drug developer Generate Biomedicines raises $400 million in US IPO

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

Feb 26, 2026, 7:58 PM EST - 6 months ago

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

Generate Biomedicines Registration statement: Registration Filing

Feb 23, 2026, 7:00 AM EST - 6 months ago

Generate Biomedicines Registration statement: Registration Filing

Generate Biomedicines aims to raise $425 million in US IPO

Feb 23, 2026, 6:45 AM EST - 6 months ago

Generate Biomedicines aims to raise $425 million in US IPO

Generate Biomedicines Registration statement: Registration Filing

Feb 13, 2026, 7:00 AM EST - 7 months ago

Generate Biomedicines Registration statement: Registration Filing

Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO

Feb 4, 2026, 5:08 PM EST - 7 months ago

Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO

Generate Biomedicines IPO Registration Document (S-1)

Feb 4, 2026, 5:02 PM EST - 7 months ago

Generate Biomedicines IPO Registration Document (S-1)

Asthma-focused AI biotech Generate Biomedicines files for a $100 million US IPO

Feb 4, 2026, 7:28 AM EST - 7 months ago

Asthma-focused AI biotech Generate Biomedicines files for a $100 million US IPO

Too026
Too026 Sep. 16 at 8:30 AM
$GENB today up to 17
1 · Reply
MavrickPete
MavrickPete Sep. 7 at 9:57 PM
$GENB First cohort fully enrolled; program has FDA Fast Track designation...
0 · Reply
CaesarZane
CaesarZane Sep. 6 at 7:24 PM
$NBIS $GENB $INTC 🚀🚀🚀 https://youtu.be/cEbwSb9BQ0U
1 · Reply
BADBRAIN
BADBRAIN Sep. 4 at 9:38 PM
$GENB At the European Respiratory Society (ERS) Congress 2026, Generate will present three posters on GB-0895 in COPD and severe asthma. The COPD poster will present safety, pharmacokinetic, and pharmacodynamic data from the ongoing Phase 1b study in adults with COPD on Sept. 8. Two additional posters will present complete Phase 1 data in asthma and the design of the ongoing SOLAIRIA-1 and SOLAIRIA-2 replicate Phase 3 studies in severe asthma.
0 · Reply
martinlees
martinlees Sep. 4 at 12:05 PM
$GENB looking at 60
0 · Reply
rventures
rventures Aug. 30 at 11:01 PM
$GENB riding this back to $25
0 · Reply
JSullivan2018
JSullivan2018 Aug. 27 at 7:51 PM
$GENB wtf
0 · Reply
DataClown
DataClown Aug. 27 at 2:32 AM
$GENB Bearish near-term. The −20.8% wasn't a verdict on the science — it was arithmetic: unlocking 68M shares onto a 60M-share float is dilution with extra steps.
0 · Reply
rventures
rventures Aug. 26 at 7:05 PM
$GENB time to get back in and sell at $20-22 again
1 · Reply
mobirdmeat
mobirdmeat Aug. 26 at 6:37 PM
$GENB Do you think this will move with $NVDA earnings ? $GRRR $ANF $BHVN
0 · Reply
mobirdmeat
mobirdmeat Aug. 26 at 6:34 PM
$GENB I am down huge that I am officially a bagholder
0 · Reply
mobirdmeat
mobirdmeat Aug. 26 at 6:23 PM
$GENB I got burnt here - chased yesteray at $20.4; and end up down huge 25% :(
0 · Reply
tfinnerty
tfinnerty Aug. 26 at 6:15 PM
$GENB meanwhile still no options on this lil fella
0 · Reply
DrLohengrin123
DrLohengrin123 Aug. 26 at 5:21 PM
$GENB Wow glad i didn’t chase this one
0 · Reply
SpiritedTwit
SpiritedTwit Aug. 26 at 3:20 PM
$GENB Joining the $GENB party 🎉 AI-driven protein design, GB-0895 already in Phase 3, Novartis partnership, and NVIDIA/NVentures backing. Definitely speculative, but there’s enough here to make this one interesting. Started a small position today. Let’s see where this goes. 👀🧬
0 · Reply
HunterXHunter12
HunterXHunter12 Aug. 26 at 6:24 AM
$GENB WHat s the story here?
1 · Reply
topstockalerts
topstockalerts Aug. 26 at 2:11 AM
$GENB that consolidation did more good than harm.
0 · Reply
fallondpicks
fallondpicks Aug. 25 at 9:43 PM
18 #stockbreakouts $EWG, $GENB, $PXF, $TS, $VGSH. Four sub-$1.
0 · Reply
DylanGFM
DylanGFM Aug. 25 at 4:48 PM
$GENB Nvidia owns 833,325 shares of GENB and publicly backs its AI‑drug‑design platform $MRNA
0 · Reply
oneg
oneg Aug. 25 at 4:37 PM
$GENB Jumped out and took loss, looks like someone is pumped up for tomorrow, ending the lock-up period.
0 · Reply
rventures
rventures Aug. 25 at 3:56 PM
$GENB sold it. Nice 45% in a 2 weeks.
0 · Reply